<DOC>
	<DOCNO>NCT01890798</DOCNO>
	<brief_summary>This single arm , open-label continued access protocol drisapersen treatment male subject Duchenne muscular dystrophy ( DMD ) dystrophin mutation correctable drisapersen-induced DMD Exon 51 skipping . The purpose continued access protocol offer pre-approval access drisapersen treatment subject DMD previously participate eligible drisapersen study . The protocol collect safety data require assure subject safety periodic efficacy data muscle function .</brief_summary>
	<brief_title>Drisapersen Duchenne Muscular Dystrophy ( DMD ) Treatment Protocol</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Prior DMD114876 subject : Subjects complete 24 week doubleblind treatment 24 week posttreatment phase study DMD114876 , OR Subjects withdraw treatment portion study DMD114876 due meeting laboratory safety stop criterion may eligible enroll extension study : laboratory parameter lead stop resolve ; benefit treatment drisapersen outweigh risk individual subject ; follow consultation GSK Medical Lead . Prior DMD115501 subject : Active subject enter openlabel extension study DMD115501 . Subjects require withdrawn DMD115501 participate . Prior DMD114044 Subjects : US citizen complete study DMD114044 another country want return US participate , upon agreement physician conduct protocol , OR Unites States citizen participate DMD114044 withdraw study due meeting laboratory safety stop criterion may eligible enroll : laboratory parameter lead stop resolve ; benefit treatment drisapersen outweigh risk individual subject ; follow consultation GSK Medical Lead upon agreement physician conduct protocol Prior DMD114349 Subjects : US citizen participate complete study DMD114044 another country enter ongoing openlabel extension study DMD114349 country outside US wish withdraw DMD114349 return US participate protocol , upon agreement physician conduct protocol . Subjects require withdraw DMD114349 participate protocol . Baseline platelets 150 x 109/Liters ( L ) great history thrombocytopenia . Continued use glucocorticosteroids minimum 60 day prior protocol entry reasonable expectation subject remain steroids duration protocol . Changes cessation glucocorticosteroids discretion physician conduct protocol consultation subject/parent . The GSK Medical Lead must notify timely manner . Willing able comply protocol requirement procedure ( exception assessment require subject ambulant , subject lose ambulation ) . Able give inform assent and/or consent writing sign subject and/or parent ( ) /legal guardian ( accord local regulation ) . Subject serious adverse experience meet safety stop criterion remain unresolved protocol DMD114876 , opinion physician conduct protocol could attributable study medication , ongoing . Once resolve , subject may eligible enroll follow consultation GlaxoSmithKline ( GSK ) Medical Lead . Use anticoagulant , antithrombotics antiplatelet agent , previous treatment investigational drug , except drisapersen , within 28 day first administration drisapersen .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>GSK2402968</keyword>
	<keyword>drisapersen</keyword>
</DOC>